Skip to content

Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry

Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02100904
Acronym
ULTRA Registry
Enrollment
578
Registered
2014-04-01
Start date
2014-05-01
Completion date
2026-06-30
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Fibroids

Keywords

Fibroids, Radiofrequency ablation, Myomectomy

Brief summary

The ULTRA Registry is a nationwide observational arm of the ULTRA trial. Data from the ULTRA Registry will be used to evaluate the long-term safety and efficacy of laparoscopic RF ablation (Acessa). The ULTRA Registry will recruit women age 21 or older who plan to undergo or have undergone laparoscopic RF ablation (Acessa) or myomectomy within the United States. Participants will be recruited through study materials distributed at clinical offices across the country where gynecologists are performing laparoscopic RF ablation (Acessa). Study participants will consent to participate in a 3 year prospective study conducted by UCSF but the fibroid procedure will be performed by the study participants' own gynecologist. We will evaluate changes in fibroid-related symptoms from pre-treatment values to 6, 12, 18, 24, 30, and 36 months after RFA (Acessa). We will determine long-term efficacy of RFA (Acessa) by evaluating the rate of re-treatment for symptomatic fibroids after the RFA (Acessa) procedure versus myomectomy. Participants will be asked for permission to review their medical records to assess surgical and pregnancy outcomes. UC San Francisco will have oversight of all scientific and administrative aspects of the study. All study data will be stored securely in a HIPAA compliant, secure database monitored by the UC San Francisco Coordinating Center.

Interventions

PROCEDUREMyomectomy of fibroids

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Planning to undergo or have undergone\* RF ablation (Acessa) or myomectomy (laparoscopic or abdominal) for treatment of uterine fibroids. * Able to give informed consent * Speak English or Spanish * Women enrolled at contracted clinical sites must enroll prior to their RF ablation treatment

Exclusion criteria

* \<21 years of age * Plan to undergo hysteroscopic myomectomy

Design outcomes

Primary

MeasureTime frameDescription
Changes in fibroid-related symptoms after the RFA or myomectomy procedure.Baseline to 3 yearsWe will use standard questionnaires for women with fibroids to assess changes in fibroid symptoms including menstrual pattern and flow and overall quality of life.

Secondary

MeasureTime frameDescription
Rate of re-intervention for recurrent fibroid symptoms following the RFA or myomectomy procedure.Baseline to 6 weeks
Operative complicationsBaseline to 6 weeksOperative complications are rare but may include excessive blood loss, uterine or pelvic infection, injury to organs adjacent to uterus such as bowel or bladder.
Pregnancy rate after the RFA or myomectomy procedure.Baseline to 3 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORVanessa Jacoby, MD

University of California, San Francisco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026